My two cents: this should be the rule and not the exception - and it should not be up to the companies. Data from negative trials must be made available.

"In 2018, a group of drug companies agreed to do something unusual in their normally secretive industry. They decided to share confidential clinical data from six failed trials with each other and a select group of specialists who had been brought together by the Alzheimer’s Association, a lobby group for patients’ rights based in Chicago, Illinois."

https://www.nature.com/articles/d41586-023-00954-w?utm_source=linkedin&utm_medium=social&utm_content=organic&utm_campaign=CONR_JRNLS_AWA1_GL_SCON_SMEDA_NATUREPORTFOLIO